1.The prognostic value of serial measurement of serum CA-125 levels during chemotherapy of epithelial ovarian cancer.
Soon Beom KANG ; Hye Sung MOON ; Seung Kew BAIK ; Byung Gi KIM ; Yong Sang SONG ; Hyo Pyo LEE
Korean Journal of Obstetrics and Gynecology 1993;36(11):3750-3760
No abstract available.
Drug Therapy*
;
Ovarian Neoplasms*
2.Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
Tao WU ; Xi Xia ZHAO ; Guo Qing WANG
Journal of Gynecologic Oncology 2018;29(4):e51-
No abstract available.
Drug Therapy*
;
Ovarian Neoplasms*
3.Intraperitoneal cisplatin chemotherapy for advanced ovarian cancer.
Ji Wook PARK ; Chan Hwa MOON ; Won Gue KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 1993;36(10):3635-3641
No abstract available.
Cisplatin*
;
Drug Therapy*
;
Ovarian Neoplasms*
4.Intraperitoneal cisplatin chemotherapy for advanced ovarian cancer.
Ji Wook PARK ; Chan Hwa MOON ; Won Gue KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 1993;36(10):3635-3641
No abstract available.
Cisplatin*
;
Drug Therapy*
;
Ovarian Neoplasms*
5.A case of neoadjuvant chemotherapy with taxol / carboplatin in advanced epithelial ovarian cancer.
Korean Journal of Obstetrics and Gynecology 2000;43(10):1874-1878
No abstract available.
Carboplatin*
;
Drug Therapy*
;
Ovarian Neoplasms*
;
Paclitaxel*
6.A Case of Cerebral Metastsis Secondary to Primary Epithelial OvarianCarcinoma : in Complete Responder to Chemotherapy and Surgery.
Korean Journal of Obstetrics and Gynecology 1997;40(3):675-680
Cerebral metastses secondary to primary epithelial ovarian carcinoma are unusual. The incidence was estimated under 1%, but some authors reported higher incidence than previously reported data. Recently, we experienced a case of cerebral metastasis secondary to primary epithelial ovarian cancer. We present this case with review of brief related literatures.
Drug Therapy*
;
Incidence
;
Neoplasm Metastasis
;
Ovarian Neoplasms
7.In Vitro Growth Inhibition of Human Ovarian Cancer Cell Lines by Mitosene Analogues.
Dong Soo CHA ; Soo Kie KIM ; Chan Mug AHN ; Sun Ju CHOI ; Yoon Sun PARK ; Sang Won HAN
Journal of the Korean Cancer Association 1997;29(3):437-444
No abstract available
Cell Line*
;
Drug Therapy
;
Humans*
;
Ovarian Neoplasms*
8.Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
Hiroko MACHIDA ; Koji MATSUO ; Takayuki ENOMOTO ; Mikio MIKAMI
Journal of Gynecologic Oncology 2019;30(6):e113-
No abstract available.
Drug Therapy
;
Japan
;
Joints
;
Ovarian Neoplasms
9.External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Jung Yun LEE ; Young Shin CHUNG ; Kiyong NA ; Hye Min KIM ; Cheol Keun PARK ; Eun Ji NAM ; Sunghoon KIM ; Sang Wun KIM ; Young Tae KIM ; Hyun Soo KIM
Journal of Gynecologic Oncology 2017;28(6):e73-
OBJECTIVE: The chemotherapy response score (CRS) system based on histopathological examination has been recently proposed for tubo-ovarian high-grade serous carcinoma (HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study was aimed at validating the CRS system in an external cohort of tubo-ovarian HGSC patients. METHODS: This study included 110 tubo-ovarian HGSC patients who underwent NAC followed by interval debulking surgery. The 3-tiered CRS of the omental and adnexal tissue sections was determined by 3 independent pathologists. Differences in patient outcomes according to CRS were analyzed. RESULTS: The CRS system was highly reproducible among the 3 pathologists. Fleiss' kappa value and Kendall's coefficient of concordance for the omental CRS were 0.656 and 0.669, respectively. The omental CRS significantly predicted progression-free survival (PFS). The median PFS of patients whose tumors exhibited the omental CRS 1–2 (15 months) was significantly shorter than that of patients with an omental CRS of 3 (19 months; p=0.016). In addition, after adjusting for age, stage, and debulking status, the omental CRS was an independent prognostic factor for PFS of tubo-ovarian HGSC patients who were treated with NAC (adjusted hazard ratio [HR]=1.74; 95% confidence interval [CI]=1.05–2.87). CONCLUSION: The CRS system for assessing NAC response was a reproducible prognostic tool in our cohort. The application of the CRS system after NAC can improve survival estimation in HGSC patients.
Cohort Studies
;
Disease-Free Survival
;
Drug Therapy*
;
Humans
;
Ovarian Neoplasms
10.Prognostic Value of Serum CA 125 Measurment during Chemotherapy for the Patients with Epithelial Ovarian Cancer.
Eung Seon KIM ; Seon Ho KIM ; Seon Kyung LEE ; Seung Bo KIM
Korean Journal of Obstetrics and Gynecology 1997;40(11):2402-2408
Serum CA 125 was measured during early chemotherapy in 34 patients from January, 1991 to December, 1994 with ovarian cancer to investigate if serial measurmemts of antigen level could be used as a prognostic parameter. Serum CA 125 was determined after the first, second, and third course of chemotherapy. There was significant correlation between high serum CA 125 levels(>35U/ml) after the third course of chemotherapy and advanced FIGO stage, large residual tumor volume after cytoreductive surgery, but there was no significant correlation with patient age, tumor differentiation, and hitologic type. And high serum level of CA 125 after the third course of chemotherapy was significantly correlate with poor response to chemotherapy(p<0.0001), but there was no significant correlation with the finding of second-look laparotomy. CA 125 was a significant parameter in all three courses of chemotherapy but its correlation with 5-year survival was improved with the number of courses of the chemotherapy. Patientswith high serum CA 125 level(>35U/ml) after the third course had a 0% 5-year survival. This should be compared with a 89.5% 5-year survival in patients who had serum CA 125 level of 35U/ml or less(p<0.0001). As a consequence of this study, chemotherapy of patients with high CA 125 levels after the third course may be discontinued and replaced by other chemotherapy or palliative therapy.
Drug Therapy*
;
Humans
;
Laparotomy
;
Neoplasm, Residual
;
Ovarian Neoplasms*
;
Palliative Care